A549 Xenograft Model Service for NSCLC

The A549 xenograft model is a cornerstone preclinical platform for evaluating novel therapeutic strategies against non-small cell lung cancer (NSCLC). Alfa Cytology leverages decades of collective oncology expertise to deliver robust, reproducible A549 xenograft studies that accelerate your compound's path from bench to IND-enabling data.

Overview of A549 Xenograft Model for NSCLC

The A549 cell line was established in 1972 by D.J. Giard et al. from an explant culture of lung adenocarcinoma tissue obtained from a 58-year-old Caucasian male. As a hypotriploid human alveolar basal epithelial cell line, A549 retains key features of type II pneumocytes, including the capacity to synthesize lecithin and dipalmitoylphosphatidylcholine (DPPC) via the cytidine-diphosphocholine pathway. In the context of NSCLC research, A549 serves as one of the most extensively characterized adenocarcinoma models, harboring a homozygous KRAS G12S activating mutation and wild-type TP53, making it particularly valuable for studying RAS-driven oncogenic signaling, chemoresistance mechanisms, and the KEAP1/NRF2 oxidative stress response pathway.

When implanted into immunodeficient murine hosts, A549 cells form well-established tumors that recapitulate critical aspects of human NSCLC biology, including tumor growth kinetics, angiogenic potential, and response to standard-of-care agents such as paclitaxel and cisplatin. The A549 xenograft model has been validated across numerous independent studies for evaluating targeted therapies, immunotherapeutic approaches, and combination regimens, offering a reliable bridge between in vitro findings and in vivo pharmacological outcomes.

Fig 1. mRNA expression of (a) IL-10 and (b) IL-18 in A549 tumor tissues by real-time quantitative polymerase chain reaction. (Jun, Ji Hae, et al., 2023)

Cell Line Information: A549

A549 is among the most widely utilized human lung cancer cell lines in preclinical oncology, serving as both an in vitro model for type II alveolar epithelial cell function and a foundational in vivo platform for NSCLC drug development. The table below summarizes the essential characteristics of the A549 cell line.

Our Services

Alfa Cytology provides comprehensive, GLP-compliant A549 xenograft model services designed to support your preclinical oncology pipeline from lead optimization through IND-enabling studies. Our integrated platform combines rigorous cell line authentication, standardized tumor inoculation protocols, and advanced endpoint analyses—including tumor volume monitoring, biomarker profiling, and histopathological evaluation—to deliver high-quality, reproducible data that meets regulatory expectations. Whether your program requires subcutaneous flank models for rapid screening, orthotopic implantation for tissue-specific microenvironment studies, or bioluminescent/luciferase-labeled A549 derivatives for real-time tumor tracking, our scientific team tailors each study to your compound's unique mechanism of action and development milestones.

Workflow of A549 Xenograft Model Construction

Establishing a robust A549 xenograft model requires meticulous attention to cell line integrity, host selection, and standardized procedural execution. Alfa Cytology follows a rigorous, stepwise workflow to ensure consistent tumor engraftment, predictable growth kinetics, and reliable therapeutic readouts across all studies.

1. Cell Line Preparation and Quality Control: A549 cells are expanded under standardized culture conditions (F-12K medium, 10% FBS, 37°C, 5% CO₂) and subjected to comprehensive quality control, including mycoplasma testing, short tandem repeat (STR) authentication against ATCC reference profiles, and viability assessment (>95% viability required) prior to inoculation.
2. Host Selection and Acclimatization: Immunodeficient mouse strains—most commonly athymic nude (nu/nu) or NOD/SCID gamma (NSG) mice—are selected based on study objectives. Animals are acclimatized for a minimum of 5–7 days under controlled environmental conditions (22±2°C, 12-hour light/dark cycle) with ad libitum access to sterilized food and water.
3. Tumor Cell Inoculation: A549 cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free medium mixed with Matrigel® (typically 1:1 ratio) to enhance engraftment efficiency. A standardized inoculum (e.g., 5×10⁶ cells in 100–200 µL) is injected subcutaneously into the flank or orthotopically into the lung parenchyma, depending on the experimental design.
4. Tumor Monitoring and Randomization: Tumor development is monitored by palpation and caliper measurement twice weekly. Once tumors reach a predetermined volume (typically 80–150 mm³), mice are randomized into treatment groups (n≥5 per group) stratified by tumor size to minimize inter-group variability.
5. Treatment Administration and In-Life Observations: Test articles are administered according to the study protocol (route, frequency, and dose established per client requirements). Body weight, clinical signs, and tumor dimensions are recorded at defined intervals throughout the in-life phase to assess tolerability and preliminary efficacy signals.
6. Endpoint Analysis and Data Collection: At study termination, tumors are excised, weighed, and processed for downstream analyses. Endpoints include tumor growth inhibition (TGI), tumor regression rate, histopathology (H&E, IHC), biomarker expression (Western blot, qPCR, flow cytometry), and pharmacokinetic/pharmacodynamic (PK/PD) correlation as applicable.

Fig 2. A549 xenograft model construction workflow.

Case Study-A549 Xenograft Model Development

In a representative preclinical study, A549 cells were subcutaneously implanted into immunodeficient mice to evaluate the antitumor efficacy of a novel therapeutic candidate. Following tumor establishment and randomization, animals received the test compound or vehicle control according to a defined dosing schedule. Longitudinal tumor monitoring demonstrated dose-dependent tumor growth inhibition, with the high-dose cohort achieving statistically significant reduction in tumor volume compared to the control group. At study endpoint, excised tumors were analyzed by histopathology and immunohistochemistry to assess treatment-induced changes in proliferation markers (Ki-67), apoptotic indices (cleaved caspase-3), and angiogenic factors (CD31). These data supported the compound's mechanism of action and provided critical preclinical evidence for downstream development decisions.

Why Choose Alfa Cytology?

Alfa Cytology is committed to delivering scientifically rigorous, operationally efficient A549 xenograft services that align with your preclinical development timelines and regulatory requirements. Our differentiated capabilities include:

• Extensive experience with A549 and other NSCLC cell line-derived xenograft (CDX) models, ensuring high engraftment rates and reproducible tumor growth kinetics.
• Flexible study design options encompassing subcutaneous, orthotopic, and metastatic model configurations, with optional bioluminescence imaging for real-time tumor tracking.
• Comprehensive in-life and endpoint analytical packages, including tumor volume monitoring, body weight assessment, clinical pathology, histopathology, and biomarker analysis.
• Strict adherence to cell line authentication (STR profiling), mycoplasma screening, and GLP-compliant documentation standards to ensure data integrity and regulatory acceptance.
• Dedicated project management with transparent communication, milestone-driven reporting, and rapid turnaround times to keep your development program on schedule.
• Competitive pricing and scalable capacity to accommodate projects ranging from single-agent proof-of-concept studies to large-scale combination therapy screens.

Contact Us

Ready to advance your NSCLC therapeutic program with a validated A549 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and partner with Alfa Cytology for reliable, high-quality preclinical data. Our scientific team is standing by to reach out and guide your compound from early-stage evaluation through IND-enabling studies.

For research use only. Not intended for any clinical use.